Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Diwakar Davar(University of Pittsburgh), Janis M. Taube(Bloomberg (United States)), Lei Zhao(Fred Hutch Cancer Center), Arivarasan Karunamurthy(University of Pittsburgh Medical Center), Robert M. Morrison(UPMC Hillman Cancer Center), Joë-Marc Chauvin(University of Pittsburgh), Douglas J. Hartman(University of Pittsburgh), Amanda G. Paulovich(Fred Hutch Cancer Center), John A. McCulloch(National Cancer Institute), Ornella Pagliano(University of Pittsburgh Medical Center), Christopher Deitrick(University of Pittsburgh), Riyue Bao(University of Pittsburgh), Alicia M. Cole(Princess Margaret Cancer Centre), Corey Urban(University of Pittsburgh), Miriam R. Fernandes(National Cancer Institute), F. Amatore(Hôpital de la Timone), Matthew P. Holtzman(UPMC Hillman Cancer Center), Amiran Dzutsev(National Cancer Institute), Umamaheswar Duvvuri(City University of New York), Jennifer R. Fang(National Cancer Institute), Haroon A. Choudry(University of Pittsburgh Medical Center), James E. Wooldridge, Yana G. Najjar(UPMC Hillman Cancer Center), Jason J. Luke(University of Chicago), Wentao Gao(Jiangsu Province Hospital), Richard R. Rodrigues(Frederick National Laboratory for Cancer Research), Shaum Sridharan(University of Pittsburgh), Christopher Groetsch(University of Pittsburgh), Julie S. Deutsch(Johns Hopkins University), John M. Kirkwood(UPMC Hillman Cancer Center), Matthew G. Fury(Regeneron (United States)), Jeffrey R. Whiteaker, Richelle DeBlasio(University of Pittsburgh), Poonam Aggarwal(Punjab Agricultural University), Jonathan H. Badger(National Cancer Institute), Prajan Divarkar(Nanostring Technologies (United States)), Jie Sun(Duke University), Yang Jin(Guiyang Medical University), Hong Wang(Zhejiang University of Technology), Yulong Bai(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Jagjit Singh(UPMC Hillman Cancer Center), Rodrigo X. Das Neves(UPMC Hillman Cancer Center), Arthur Μ. Krieg(Celldex Therapeutics (United States)), James F. Pingpank(University of Pittsburgh Medical Center), Quanquan Ding(University of Pittsburgh Medical Center), James Patrick O'Toole(UPMC Hillman Cancer Center), David Mauro, Amy Rose(University of Pittsburgh Medical Center), Dmitri Bobilev
Cited by 60
Related Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
|Proceedings of the National Academy of Sciences|2005|56.5k
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k